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Background:  Health  policy  makers  often  have  to face  decisions  on  whether  and  how  to  incorporate  new
vaccines  into  immunisation  plans.  This  study  aims to review  and catalogue  the  relevant  current  frame-
works  and  taxonomies  on  vaccines  and  connect  these  to  the DECIDE  Evidence  to  Decision  framework
(EtD),  a general  framework  based  on  evidence-based  criteria  to guide  decision-making  on  intervention
adoption.
Methods:  We  systematically  searched  MEDLINE,  EMBASE,  Cochrane  Library  and  funding  agency  websites
from 1990  to 2013.  We  included  systematic  reviews  and  primary  studies  presenting  decision-making
tools for  community  vaccine  adoption.  We  qualitatively  summarised  the reports  by  purpose,  targeted
country,  principal  results,  and  decisional  models.  We  then  extracted  and  compared  the  dimensions
adopted  by  vaccine  frameworks  across  studies.
Results: Fourteen  studies  (ﬁve  systematic  reviews  and  nine  primary  studies)  were  included.  Several  factors
frequently  inﬂuenced  decision-makers’  views  on  vaccines:  the most  frequent  political-context  factors
considered  were Importance  of illness  or problem,  Vaccine  characteristics,  Resource  use,  and  Feasibility.
Others  such  as  Values  and  preferences  and  Acceptability  were less  consistently  reported.  We  did  not  ﬁnd
evidence  on the  reasons  why a  framework  for vaccine  adoption  differs  from  that  for decisions  on the
adoption  of an  intervention  in general,  such  as the EtD. There  are  limited  data  on  how  dimensions  are
explained  in practical  factors  and  directly  linked  to coverage  decisions.
Conclusions:  This  review  summarises  conceptual  models  and  taxonomy  of  a heterogeneous  and  evolving
area in  health  policy  decisions.  A shared  and  comprehensive  framework  on vaccine  coverage  remains
to  be  achieved  with  its single  dimensions  (epidemiologic,  effectiveness,  economic,  and  social)  valued
differently  across  studies.  A generic  tool such  as  the EtD  conceptualises  all relevant  dimensions,  and
might  reduce  inconsistencies.
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. Background
Over the past decade, several randomised controlled trials
valuating the safety or the efﬁcacy of new vaccines have been
ompleted [1]. One approved by drug regulatory agencies, some
f these vaccines, such as those for human papilloma virus and
1N1 inﬂuenza A, have been introduced into low, middle, and high-
ncome countries. Health care systems are discussing the potential
doption of other vaccines such as rotavirus, pneumococcal and
eningococcal vaccines [2,3].
New vaccines might represent major medical breakthroughs in
reventive care, while others may  have scarce or limited innovative
alue. In both cases, the production and commercialisation of newly
eveloped vaccines are likely to be more expansive than previous
nes.
From a public health perspective, health policy makers will
eed to answer questions regarding dosage, general effectiveness,
afety, impact, and expected compliance of vaccines. They must
urther make decisions between new vaccines and alternative pro-
rammes (e.g., interventions for stopping the spread of infection),
eighing the costs and expected health beneﬁts in the develop-
ent of national immunisation programmes [4]. Limited ﬁnancial
esources should be distributed in a fair and effective manner to
chieve the best possible outcomes within local rather than global
onditions, considering all direct and indirect consequences of the
mmunisation programme.
In 2005, the World Health Organisation (WHO) released the doc-
ment entitled “Vaccine introduction guidelines. Adding a vaccine to
 national immunisation programme: decision and implementation”
5]. The document has since been updated [6]. This publication
ffers decision-makers a structured and comprehensive framework
or determining the impact of one or more vaccine options, and
rovides answers to various policy questions. Other frameworks
ollowing a similar approach to the WHO  have also been proposed
e.g. Global Immunisation Strategic Framework 2011–2015) [7],
utlining useful criteria, indicators, sources of data and validation
rocesses.
The Developing and Evaluating Communication Strategies to
upport Informed Decisions and Practice Based on Evidence
DECIDE) project is a collaborative research project aimed to
evelop and evaluate communication strategies to support evi-
ence informed decisions building on the work of the Grading
f Recommendations Assessment Development and Evaluation
GRADE) Working Group and the Cochrane Applicability and Rec-
mmendations Methods Group [8–10]. As a part of the DECIDE
roject, a general framework for communicating evidence to
nform coverage decisions called Evidence to Decision (EtD) for cov-
rage is being developed [9,11]. In this context, “coverage” decision
s deﬁned as the potential provision of the intervention (i.e., vac-
ine) at no cost to the user and at the expense of the regional or
ational health system, health insurance organisations or health
oundations and charities (e.g., the GAVI Alliance). This framework
ims to be general, encompassing a wide spectrum of decisions
rom preventive to therapeutic or diagnostic interventions. The
ramework is divided into three parts: the ﬁrst presents the con-
ition and background information; the second involves a table
hat provides information identiﬁed as essential to make a partic-
lar type of decision (i.e., dimension and criteria used); the third
ummarises the components used to make the decision [9].
The aim of our study was to explore speciﬁc aspects of health
olicy decision frameworks on vaccines. We  a priori assumed that
accines differ from other drugs at least in the types of recommen-
ations or decisions involving its uptake by health care systems
e.g., clinical recommendations from an individual patient perspec-
ive or from a population perspective. Thus, we thought a generic
ramework such as the EtD may  not be suitable for vaccines. Whenine 33 (2015) 1206–1217 1207
a generic framework is applied to support speciﬁc decisions (i.e.,
vaccines), its validity and sensitivity can be limited. To fully address
the issues relevant speciﬁcally to vaccines, we  decided to system-
atically identify, summarise, and catalogue current frameworks
and taxonomies on vaccines. We  sought to then connect these
dimensions to a general framework for communicating evidence to
inform coverage decisions (i.e., the EtD framework). We  explored
differences among the existing frameworks speciﬁc to vaccines and
compared these with the wider EtD framework in order to inform
the EtD framework with speciﬁc and comprehensive dimensions
and criteria related to the adoption or modiﬁcation of immunisa-
tion policies.
2. Methods
The research was  structured in three phases. In the ﬁrst phase,
we developed a comprehensive literature search to identify con-
ceptual frameworks on vaccines. In the second phase, we  identiﬁed
and synthesised the main dimensions and constructs suggested. In
the third phase, we provided speciﬁc suggestions on target vaccine
adoption decisions to inform the EtD framework.
2.1. Criteria for considering studies for inclusion
We included systematic reviews, which summarised frame-
works for vaccine adoption decision-making. We considered as
a systematic review any review of a clearly formulated ques-
tion that uses systematic and explicit methods to identify, select,
and critically appraise relevant research, and to collect and ana-
lyse data from the studies that are included in the review [12].
We excluded studies presenting: (a) no frameworks for vaccine
adoption decision-making; (b) providing a narrow focus on a sin-
gle dimension (e.g., cost-effectiveness studies); (c) basic scientiﬁc
research on vaccine development; and (d) data on non-human vac-
cinations.
To ensure the comprehensiveness of our review, we  also
included primary studies (i.e., conceptual studies describing or
proposing a set of decision criteria or a decision-making tool),
which were not included in the selected reviews. To identify these
primary studies providing a new approach not previously described
in the included reviews, we crosschecked the reference lists of all
included reviews against the output of the search strategies.
All relevant studies were included, regardless of their language
or publication status.
2.2. Search methods for identiﬁcation of eligible studies
We searched for systematic reviews published between January
1990 and March 2013 on the following bibliographic databases:
MEDLINE, EMBASE, The Cochrane Library (i.e., Cochrane Database
of Systematic Reviews, Database of Abstracts of Reviews of Effects,
Health Technology Assessment Database, and NHS Economic Eval-
uation Database). Our search strategy featured the following
keywords: decision-making, vaccination, decision aid, model, frame-
work, health policy, and immunisation programmes. In order to
consider primary studies that were not included in reviews, we per-
formed a sensitive search strategy on MEDLINE, EMBASE and The
Cochrane Central Register of Controlled Trials between March 2010
and March 2013 (the ﬁnal date of the searches reported in Burchett
et al. [13], the most recent systematic review on our subject).
In addition to bibliographic databases, we  searched the fol-
lowing websites: WHO, National Institutes of Health, Centers for
Disease Control and Prevention, European Centre for Disease Pre-
vention and Control and Pan American Health Organisation. To
identify papers that were not indexed in the above-mentioned
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Full-text articles excluded, with reasons:
- No decisional frameworks (n = 53)
- The framework (for primary studies) was
included in a SR (n = 9)
- A vaccine economic analyses (n = 10)
- Not stud y design of interest (n = 13)
- Focused on  no n-hu man vacc inati ons (n = 1)
Records identified through primary 
study databases searching (2010 -2013)
(n = 99 7)
Records identified through systematic 
reviews (SRs) databases searching 
(199 0-2013 )
(n = 292 0)
Full-text articles assessed for 
eli gibilit y
SRs (n = 23)
Primary studies (n = 75)
Stud ies includ ed in qu alit ati ve 
synthesis
(n = 14)
- 5 SRs (2 found  by  hand  sea rches)
- 9 primary stud ies
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atabases, we examined the reference lists of all included studies
or additional literature.
.3. Data collection and analysis
.3.1. Study selection
Two authors independently examined the titles and abstracts
etrieved by the search strategy and assessed the full-text articles
f the potential relevant studies. Any disagreement was  resolved
y discussion. We  documented the reasons for excluding studies.
 study ﬂow diagram according to the PRISMA statement [14] can
e found in Fig. 1.
.3.2. Data extraction and management
We  extracted information on the purpose of the study, the
ublication date, the origin and targeted country, primary results
nd decisional frameworks and taxonomy used. All doubtful infor-
ation were presented to a third author and discussed before
nclusion. Given the heterogeneity of study designs, their descrip-
ive nature and lack of a standard methodology, we did not assess
he methodological quality of the included studies.
.4. Development and analysis of the conceptual framework
We  ﬁrst recorded all of the components about coverage rec-
mmendations proposed in the included studies, assessing the
requency of each. We were inclusive, as we did not exclude items
ased on their relevance or frequency.
We then used the EtD model to structure the identiﬁed
omponents [8,9], aligning the terminology used in the vaccine
rameworks to corresponding ones of the EtD. In particular, we
rganised our vaccine framework to present the information by
imensions and criteria. In EtD, the broader headings involve the
ain domains to be assessed (i.e., burden of illness or problem, ben-
ﬁts and harms, values and preferences, resources use, equity, and
easibility).  The criteria for each domain are then presented as
ubheadings (e.g., incidence, efﬁcacy, cost-beneﬁt, etc.) placed atiagram.
subsequently narrow levels of the proposed hierarchy. Again, we
retained all components found across included studies, although
we might have modiﬁed the relationship between the domains and
the criteria as intended by the original study authors.
This entire process was carried out by a multi-disciplinary group
of 12 review authors, including methodologists, policy makers,
economists, and medical editors. The authors participated in exten-
sive face-to-face and electronic correspondence. A few authors met
in person on several occasions to consider all comments and reﬁne
the conceptual framework. We regularly circulated the document
among authors who  approved the ﬁnal decisional framework.
3. Results
3.1. Search results
We  identiﬁed 2920 reference citations after excluding the dupli-
cates. Among them, 98 potentially relevant publications were
retrieved in full text (Fig. 1). Eighty-six publications were excluded
because they: lacked a decisional framework for community vac-
cine adoption (n = 53) or an appropriate study design (e.g., narrative
reviews) (n = 13); provided a narrow focus on a single dimension
(e.g., economic analysis of vaccines) (n = 10); focused on non-
human vaccinations (n = 1), or addressed a framework already
described in an included review(n = 9)(see additional ﬁle 1). We
identiﬁed three additional systematic reviews [13,15,16] as well
as nine primary studies [17–25] that were not included in the
systematic reviews. We  selected an additional two reviews through
hand searches [26,27], leading to a total of 14 included publications.
3.2. Description of systematic reviews and primary studies
includedAll systematic reviews included were published after the year
2000. All were in English and the locations of the primary authors
were from Canada [26], United Kingdom [13], Italy [27], Austria
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15], and Mexico [16]. Each review included a range of 5–85 primary
tudies.
Two of the reviews focused on developing a theoretical frame-
ork to support rational vaccination decision-making based on the
vailable scientiﬁc literature [15,27], while the reviews of Bryson
t al. [26] and Burchett et al. [13] reviewed the literature on
ational decision-making regarding the adoption of new vaccines.
he former included the characteristics of National Immunization
echnical Advisory Groups (NITAGs), which provide expert advice
o government decision-makers. The latter analysed the frame-
orks included using a grounded theory approach to search for
hemes and categories that emerged from the criteria included. The
eview by Tapia-Conyer et al. [16] assessed the evidence-basis of
he Commission for the Future of Vaccines in Latin America (COF-
AL) and feasibility in order to discuss each recommendation in the
ontext of existing vaccine-preventable diseases control strategies.
The nine primary studies were in English language. Of these,
even targeted different geographic and cultural contexts: two
ublications focused on a middle-income country (South Africa)
18,21], one on low to middle-income countries [24], two on
he national immunisation policy of developed and high-income
ountries (United States, South Korea) [17,25], while two was
pplied to malaria-endemic countries [19,22]. The remaining two
tudies focused on accelerating the adoption of new vaccines in
lobal Alliance for Vaccines and Immunization (GAVI) eligible
ountries [23] as well as a proposal for embracing the GRADE
pproach in the development of immunisation related WHO  rec-
mmendations [20].
We  present a qualitative description of the ﬁve systematic
eviews and the nine primary studies in additional ﬁles 2 and 3.
.3. The conceptual framework
For each publication, we extracted the dimensions and the crite-
ia proposed as well as the use of a methodologically rigorous
ystem to develop the framework (e.g., GRADE approach) (Table 1).
We then removed redundant terms of similar concepts (e.g.,
economical and ﬁnancial issues” or “economic data”) across stud-
es and identiﬁed 10 dimensions repeated across the frameworks:
mportance of illness or problem, Vaccine characteristics (beneﬁts
nd harms), Values and preferences, Resource use, Impact of vaccine,
cceptability, Feasibility, Equity and ethical considerations, Legal and
olitical considerations,  and Decision-making. We  quantiﬁed the fre-
uency of each dimension across the conceptual frameworks in the
ncluded studies (Table 2). The most common dimensions were:
mportance of illness or problem, Vaccine characteristics, Resource use,
ecision-making and Feasibility.
We  extracted the criteria reported in the frameworks, organised
hem into the 10 dimensions identiﬁed, and assessed the frequency
f each (Table 3). The most common criteria report across frame-
orks was Health economic analyses. The criteria Vaccine efﬁcacy
nd effectiveness and Vaccine safety,  which were under the dimen-
ion Vaccine characteristics (beneﬁts and harms),  were reported in
lmost all frameworks. In the dimension Importance of illness or
roblem, the criteria Incidence, Prevalence,  Mortality, Social impact
nd Speciﬁc risk groups were most frequently mentioned.
Regarding the use of a methodologically rigorous system to
nform the frameworks in included studies, Ahmed et al. [17],
uclos et al. [20], Piatti [27] and Tapia-Conyer et al. [16], proposed
he use of GRADE approach [10] for the information about the
accine effectiveness and safety. Piatti [27] and Blecher et al. [18]
ndicated how they obtained the data to inform each dimension
f the framework. For example, Blecher et al. [18] noted that their
imension Burden of disease was informed by data reported by the
ational Department of Health; their dimension Effectiveness of the
accine was informed by data from published studies in reputableine 33 (2015) 1206–1217 1209
international journals, if possible, meta-analysis or Cochrane
reviews (see Table 1).
Eight of the frameworks analysed in Table 1 [16–23,25–27]
reported that they considered guidance and recommendations
from WHO  guidelines [5].
After carefully reviewing the frequency, hierarchy, and recip-
rocal relationship of the vaccine framework components reported
across studies, and standardizing the terminologies to develop our
10 dimensions and criteria, we  proceeded to link the 10 dimensions
to those of the general EtD framework, grouping some dimensions
together. In fact, we were able to consider dimensions speciﬁ-
cally proposed for vaccines to relate to other interventions such
as drugs. The concepts outlined in the EtD were comprehensive,
allowing us to align constructs and criteria proposed in the vac-
cines frameworks with those of the EtD. Various dimensions such
as Importance of illness or problem, vaccine characteristics and impact
of the immunisation programme, and resource use were consistently
repeated across vaccine frameworks, despite small differences in
the exact terms used to describe each. For instance, variations to
describe the dimension Importance of illness or problem included
burden of illness, seriousness of the problem, and number of peo-
ple affected; the terms vaccine beneﬁts and harms and impact of
vaccination or immunisation programmes were used interchange-
ably to signify vaccine characteristics.  These terms were grouped
under the umbrella of the EtD dimension named vaccine charac-
teristics and impact of the immunisation programme. In other cases,
the relationship between vaccine frameworks and the EtD frame-
work was  less straightforward. For instance, Acceptability, Legal
and political considerations,  and Decision-making were placed under
the umbrella of Feasibility.  Thus, our ﬁnal framework may  have
altered the original constructs intended by authors in the original
papers.
Table 4 presents the six dimensions of the EtD adapted to the
vaccine context. The dimensions are Burden of disease, Vaccine
characteristics and impact of immunisation programme, Values
and preferences, Resource use, Equity and Feasibility. Each dimen-
sion is followed by a brief description and its corresponding criteria.
For example, the main criteria for the Burden of disease dimension
includes Frequency of the disease/condition (e.g., incidence), Sever-
ity of the disease/condition (e.g., mortality), and Social impact of the
condition (e.g., hospitalisation rate).
4. Discussion
This review analysed existing frameworks on the adoption of
new vaccines in order to develop a comprehensive strategy that
includes the most relevant and critical components for decision-
makers. The dimensions proposed across vaccine frameworks
aimed to inform and support coverage decisions (e.g., decisions by
third party payers about whether and how much to pay for vac-
cines). The taxonomy of different frameworks featured a sufﬁcient
level of overlap. Overall, Burden of disease, Vaccine characteris-
tics, Resource use, Decision-making, and Feasibility were frequently
reported across frameworks as the key factors to be considered
in vaccine adoption decision-making, while Values and preferences
and Acceptability were less consistently reported. These dimensions
largely overlapped with those recommended for the assessment
of any technology by policy-makers [28]. We  a priori thought
that a framework on vaccines would differ from that of other
interventions such as drugs. However, after creating the frame-
work and comparing it with EtD, we found that there were large
areas of overlap such that the EtD was helpful in structuring the
dimensions of the vaccine framework. It is important that the
dimensions address pragmatic factors and directly link to coverage
decisions.
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Table  1
Conceptual frameworks and empirical approaches analysed.
Studies General description Dimensions and criteria
Ahmed et al., 2011 [17] The framework is based on the
Grading of Recommendations
Assessment, Development and
Evaluation (GRADE) approach [10].
- Balance of beneﬁts and harms: review of the baseline risk for disease and the
expected relative and absolute effects on vaccination on health outcomes.
-  Type of evidence: evidence is grouped into four categories, with the order reﬂecting
the level of conﬁdence in the estimated effect of vaccination on health outcomes.
-  Values and preferences: relative importance of outcomes related to beneﬁts, harms
and  cost.
- Health economic analyses: cost-beneﬁt, cost-utility, cost-effectiveness.
Blecher et al., 2012 [18]
Ngcobo and Cameron
2012 [21]
The framework considers guidance
and recommendations from WHO
[5]. The decision to introduce a
new vaccine in South Africa is
based on local data.
- Disease burden and public health priority: incidence, morbidity and mortality of the
condition; the public health signiﬁcance of the condition (Data reported by the
National Department of health).
-  Efﬁcacy and safety (Published studies in reputable international journal, if possible
meta-analysis or Cochrane reviews).
- Cost-effectiveness: local studies are usually required, given very different cost
structures across countries.
-  Total cost and affordability: depends on ﬁscal space, prioritisation, success in price
negotiations and contracting.
-  Feasibility of implementation and availability of a credible implementation plan (If
there are doubts about feasibility, pilot studies may  be useful).
-  International guidelines and advice of the South African National Advisory Group on
Immunisation (NAGI) and other local and international experts.
-  Political process: besides the technical aspects, the budget process also involves
communication between the Ministers of Health and Finance and approval by a wider
committee of Ministers, the national Cabinet and Parliament.
Brooks and Ba Nguz, 2012
[19]
Milstien et al., 2010 [22]
The framework considers guidance
and recommendations from WHO
[5] for introducing new vaccines
for malaria.
- Malaria disease burden: reported and conﬁrmed cases by age group; reported
malaria-related deaths by age group; malaria epidemiology proﬁle by district; malaria
cases in pregnant women and HIV + population.
-  Other malaria interventions: impact of current malaria interventions; coverage of
current malaria interventions; cost-effectiveness estimates of current malaria
interventions.
-  Malaria vaccine impact: impact on mortality and morbidity by age group.
-  Economical and ﬁnancial issues: cost-effectiveness estimates of malaria vaccine.
-  Malaria vaccine efﬁcacy, quality and safety: adverse events; interaction with other
vaccines; efﬁcacy.
Bryson et al., 2010 [26] Factors considered by countries
when making recommendations
by presence of NITAGs.
- Burden of disease
- Economic evaluation
- Feasibility of local vaccine production
- Feasibility of recommendation
-  Recommendations of other countries
-  Public perception
- Vaccine safety and vaccine effectiveness
Burchett et al., 2012 [13] Nine broad categories of criteria
which may  inﬂuence decisions on
vaccine adoption.
- Importance of the health problem: burden of disease data, political priority, costs of
disease, perceptions of importance.
- Vaccine characteristics: efﬁcacy, effectiveness, safety, deliver issues.
-  Immunisation programme considerations: feasibility, supply.
-  Acceptability
-  Accessibility, equity and ethics.
-  Financial/economic issues: economic evaluation, incremental costs, funding sources,
vaccine price, ﬁnancial sustainability, affordability.
-  Impact: impact on health outcomes and on non-health outcome, effect of
co-administration, risks of serotype replacement.
-  Alternative interventions: cost–effectiveness of alternatives, effectiveness of
alternatives.
-  Decision-making process: Evidence sources/quality of evidence, actors involved,
procedures, cues to action.
Cho,  2012 [25] The framework considers guidance
and recommendations from WHO
for introducing new vaccines in
Korea [5].
- Disease burden in Korea: clinical characteristics of the disease, incidence, mortality,
and case fatality rates.
-  Analyzes data on the efﬁcacy, effectiveness, and safety of the vaccine: Sources of
information on the vaccine include clinical trials conducted both in Korea and in other
countries, WHO  position papers, recommendations published by the U.S  Centers for
Disease Control and Prevention and the European Centre for Disease Prevention and
Control.
-  Economic data: the cost, affordability, and ﬁnancial sustainability of implementing
the new vaccine programme, as well as the vaccine’s cost-effectiveness.
-  Recommendations by sub-committees and the KCDC: isolation of the patients, the
prophylactic management among the patient’s contacts, the diagnostic methods, the
disease surveillance and the immunisation.
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Table  1 (Continued)
Studies General description Dimensions and criteria
Duclos et al., 2012 [20] The framework considers guidance
and recommendations from WHO
[5] adopting the GRADE approach
[10].
- Epidemiologic features of the disease: disease burden (including age speciﬁc
mortality, morbidity, and social impact), speciﬁcs risk groups, epidemic potential,
disease occurrence over time (i.e., secular trends), serogroup or serotype distribution
(for serogroup or serotype speciﬁc vaccines), changes in epidemiological features over
time.
-  Clinical characteristics of the targeted disease: clinical management, disease severity
and  fatality, primary/secondary/tertiary care implications, long-term complications
and  medical care requirements.
-  Vaccine and immunisation characteristics: efﬁcacy, effectiveness and population
impact of the vaccine (including herd immunity), safety, indirect effects, cold chain
and logistical concerns, vaccine availability, vaccine schedule, social and
programmematic acceptability of the schedule, ability to reach the target populations,
ability to monitor programme impact.
-  Economic considerations: cost of illness, vaccine and vaccine delivery costs, potential
for vaccine price reductions, cost-effectiveness of immunisation programmes,
affordability of immunisation.
- Health system considerations: possible interactions with other interventions and
control strategies, possible impact of vaccine adoption on the wider health system.
-  Social impacts
- Legal considerations
- Ethical considerations
Levine et al., 2010 [23] This is proposed framework based
on observations of the process and
drivers of new vaccine adoption in
Global Alliance for Vaccines and
Immunisation (GAVI) eligible
countries. Considers guidance and
recommendations from WHO  [5].
Establish and organise evidence:
-  Epidemiology and burden of the disease (including the distribution of serotypes or
strains if relevant to vaccine policies).
-  Evidence based on the safety, efﬁcacy and relative cost effectiveness of the vaccine as
a  solution.
Establish supportive global policies:
-  Vaccine recommendations.
-  Financing policies
- Procurement mechanism
Translate polices into local action:
-  Political will to implement
- System to deliver and monitor
Makinen et al., 2012 [24] Principal factors considered in
decision-making processes of new
vaccine adoption in
lower-middle-income countries
(LMICs).
- Burden of disease data (e.g., mortality and morbidity)
- Cost related drivers: vaccine market information, cost-effectiveness, budget impact
and  affordability, and available ﬁnancing.
-  Other decision-making factors: the experience of neighbouring countries, access to
adequate procurement mechanisms and the role played by global/regional bodies to
engage countries.
- Recommendations include making epidemiological data and vaccine market
information accessible to countries, building and reinforcing related analysis capacity,
and promoting more efﬁcient procurement mechanisms such as pooling.
Piatti,  2011 [27] The decision-making procedure is
divided in ﬁve analytical steps.
For each step are provided
methods and indicators, one of
them is the GRADE approach [10].
- Step (1) Safety: Adverse Events (nature and frequency); Risk factors and groups at
risk; Biological effects (biological disequilibrium) of the vaccine.
-  Step (2) Medical-Socio-Sanitary Aspects: Burden of disease, including the social
impact of the disease; efﬁcacy, vaccine coverage.
- Step (3) Cost-efﬁcacy analysis: direct and indirect cost, modelling; discounting;
vaccine effectiveness; alternative scenario evaluation.
-  Step (4) Other implementation-related aspects: legal aspects; ethical aspects and
equity.
-  Step (5) Priority: Integration of the above-mentioned points with the sense of
urgency for introducing it.
Piso  and Wild, 2009 [15] The decision-making procedure is
divided in seven analytical steps.
Elements belonging to the ﬁrst
step were considered more
important and incisive in shaping
the decisional process than the
following ones.
- Step (1) Public health relevance and alternative measures, immunisation strategy,
conformity of programmes, research questions.
-  Step (2) Disease considerations: burden of disease, clinical manifestations, current
treatment, epidemiology, risk groups and risk factors, social impact and other
preventives measures; Vaccine considerations: vaccine characteristics, supply,
administration schedule, immune response, efﬁcacy and utilisation, population
effectiveness and safety.
-  Step (3) Cost-effectiveness analysis.
-  Step (4) Considerations on acceptability and feasibility of the new programme, equity
and  ethical implications, legal and political considerations, potential side effects.
-  Step (5) Final decision: decision-making process itself.
-  Step (6) Implementation.
- Step (7) Surveillance of vaccine coverage and utilisation, of epidemiologic changes,
the frequency and nature of adverse events, immune surveillance and re-evaluation
(revision).
Tapia-Conyer et al. [16] The evidence-basis of the
Commission for the Future of
Vaccines in Latin America
(COFVAL) and feasibility.
- Burden of disease and vaccine coverage
- Epidemiological surveillance
- National health accounts
-  Regional vaccination reference schemes
-  Professionalising immunisation policies and practices
-  Vaccine Advisory Committees
- Innovative ﬁnancing mechanisms for purchasing vaccines
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Many of the dimensions and criteria presented in the included
systematic reviews and primary studies were broad, lacking practi-
cal details for effective application in the evaluation or comparison
of vaccine strategies to guide vaccine adoption decision-making.
The beneﬁt and safety of vaccines, for example, were not suf-
ﬁciently addressed. At the same time, most frameworks were
generally qualitative: they did not report key issues such as the
study designs to privilege, how to assess the risk of bias, how to ana-
lyse beneﬁts and risks (e.g., which relative and absolute measures
to use), the value to award patient reported outcome measures and
the minimal important differences.
In order to be effective in their implementation, dimensions and
criteria should have supporting documents that present summa-
ries of quantitative and qualitative information with graphical and
tabular displays.
Governmental immunisation technical advisory panels advise
regional and national authorities on decisions to introduce new
vaccines or to adjust existing immunisation strategies. These
authorities are commissioned to perform their own analyses (e.g.,
effectiveness or economic) based on existing studies that are not
fully generalisable to local contexts due to differences such as
disease epidemiology, vaccine-speciﬁc issues (e.g., distribution
and replacement of serotypes), magnitude of estimated herd
immunity effects, local immunisation strategies, effective cover-
age, local health care systems, budgets and vaccination policies
[29,30]. The panels are likely to face difﬁculty re-adapting or
re-interpreting data pertaining to relevant vaccine dimensions
and criteria, which may  introduce several problems and lower
the quality of their recommendations. Policy makers must often
support recommendations on the introduction of new vaccines
without a transparent, structured and independent assessment
process. This frequently occurs in situations characterised by
considerable external pressure from the general public and those
with vested interests [31–33]. Expert opinions may  vary greatly as
the unstructured approach leads to selective reporting of dimen-
sions that conﬁrm a priori beliefs [34]. A structured approach is
necessary to guide stakeholders through the process, prompting
them to consider all available evidence, including less comfortable
topics such as the harms of the intervention [35].
The DECIDE project aims to provide empirically-based infor-
mation on how recommendations are formulated and performed
to support coverage decisions [8]. This approach is building on
the substantial experience and knowledge of the GRADE Work-
ing Group [10]. In our study, we compared the DECIDE approach
to other frameworks, revising it to speciﬁcally target vaccine adop-
tion decisions. There is limited empirical research on how to convey
detailed information to policy makers on adopting and implemen-
ting new vaccinations. No studies have examined the impact of
a decisional framework on vaccines for policy makers. However,
the lack of any structured framework and mechanism to ensure
equitable access to vaccines and other beneﬁts from research on
infectious diseases raised controversies and tensions over the past
years [36–38]. The limited results produced by these negotiations
have stimulated calls for a structured global framework to improve
equitable access to vaccines [39].
4.1. Limitations
The main limitation of our study is the absence of a critical
appraisal of studies included in our framework. Thus, some of the
conclusions of this review may  come from studies that are sus-
ceptible to bias. We  also analysed the frequencies of dimensions
combining systematic reviews and primary studies. Dimensions
proposed by systematic reviews might have greater value than
those proposed in primary studies. Moreover, we focused only on
vaccine frameworks. The age of the primary studies included in the
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Table 3
Criteria considered across conceptual frameworks and empirical approaches.
Dimension Criteria Studies mentioning criteria and frequency
Ahmed
et al., 2011
[17]
Blecher
et al., 2012
[18]
Ngcobo and
Cameron
2012 [21]
Brooks and
Ba-Nguz
2012 [19]
Milstien
et al., 2010
[22]
Bryson
et al. 2010
[26]
Burchett
et al. 2012
[13]
Cho 2012
[25]
Duclos
et al., 2012
[20]
Levine
et al., 2010
[23]
Makinen
et al., 2012
[24]
Piatti
2011
[27]
Piso and
Wild 2009
[15]
Tapia-
Conyer
et al. 2013
[16]
Total
Importance of
illness or
problem
Burden of disease data x x x x x x 6
Prevalence x x x x 4
Incidence x x x x x 5
Mortality/Case fatality
rates
x x x x x 5
Morbidity x x x 3
Social  Impact x x x x x 5
Hospitalisations x 1
Risk  factors x x 2
Speciﬁc  risk groups x x x x x 5
Disease  occurrence over
time (i.e., epidemic,
secular trends)
x 1
Serogroups or serotypes
distribution
x x 2
Clinical  features of the
disease
x x x 3
Clinical  management x x 2
Cost  of disease x x 2
Perceptions of
importance
x x 2
Other  preventives
measures
x 1
Vaccine
characteristics
(beneﬁts  and
harms)
Vaccine characteristics x x 2
Biological effects of the
vaccine
x x x 3
Vaccine efﬁcacy and
effectiveness
x x x x x x x x x x x 11
Vaccine coverage x 1
Population impact of the
vaccine
x 1
Herd  immunity x 1
Vaccine safety x x x x x x x x x x x 11
Interaction with other
vaccines
x 1
Indirect  effects x 1
Cold  chain and logistical
concerns
x x 2
Vaccine administration
schedule
x x x 3
Social  and programmatic
acceptability of the
schedule
x 1
Values  and
preferences
Relative importance of
outcomes related to
beneﬁts
x 1
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Table 3 (Continued)
Dimension Criteria Studies mentioning criteria and frequency
Ahmed
et al., 2011
[17]
Blecher
et al., 2012
[18]
Ngcobo and
Cameron
2012 [21]
Brooks and
Ba-Nguz
2012 [19]
Milstien
et al., 2010
[22]
Bryson
et al. 2010
[26]
Burchett
et al. 2012
[13]
Cho 2012
[25]
Duclos
et al., 2012
[20]
Levine
et al., 2010
[23]
Makinen
et al., 2012
[24]
Piatti
2011
[27]
Piso and
Wild 2009
[15]
Tapia-
Conyer
et al. 2013
[16]
Total
Relative importance of
outcomes related to
harms
x  1
Relative  importance of
outcomes related to cost
x 1
Economic
considera-
tions/Resource
use
Health  economic
analyses (e.g.,
cost-beneﬁt, cost-utility,
cost-effectiveness)
x  x x x x x x x x x x x 12
Direct  and indirect cost x 1
Vaccine  and vaccine
delivery costs
x x x x x 5
Potential for vaccine
price reductions
x 1
Affordability of
immunisation
x x x 3
Cost-effectiveness of
alternatives
interventions
x x x 3
Incremental costs x 1
Funding  sources x x 2
Financial sustainability x x x 3
Impact  of
vaccination
Impact on health
outcomes
x x x 3
Impact  on non-health
outcomes
x x 2
Effect  of
co-administration
x 1
Risk  of serotype
replacement
x 1
Other  impact x 1
Acceptability Acceptability of the
vaccine
x x 2
Public  perception x 1
Feasibility Feasibility  of the
implementation of the
programme
x x x x 4
Feasibility of local
vaccine production and
vaccine availability
x x x 3
Feasibility of
recommendation
x x 2
Ability  to reach the target
populations
x x 2
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Impact of vaccine
adoption on the wider
health system.
x x 2
Ability  to monitor
programme impact (i.e.,
surveillance)
x x x x 4
Epidemiological changes
of the disease (after
vaccine introduction)
x 1
Equity  and
Ethical
considerations
Ethical considerations x x x 3
Accessibility, equity and
ethics
x x x 3
Legal  and political
considerations
Legal considerations x x x x x 5
Decision-
making
Decision-making process x x x x 4
Evidence sources/quality
of evidences
x x 2
Impacts and coverage of
other interventions for
the disease
x x x 3
Population coverage x 1
Priority  x 1
Actors  involved x 1
Procedures x 1
Cues  to action x 1
Recommendations of
other countries
x 1
International guidelines
and expert advice
x 1
Political process x x 2
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Table  4
Proposed conceptual framework to support vaccine adoption and coverage decisions in a health system.
Dimensions Description Questions Criteria
Burden of disease Description of epidemiology,
clinical features and sequelae of
the disease/condition in terms of
public health consequences.
Is the disease/condition severe?
Is the disease/condition frequent?
Is the vaccination a priority?
- Frequency of the disease/condition (e.g., incidence,
prevalence, secular trends).
- Severity of the disease/condition (e.g., mortality,
morbidity).
- Social impact of the disease/condition (e.g.,
hospitalisation rate, sickness absenteeism, high-risk
groups, clinical features, perception of importance,
other preventive measures)
Vaccine characteristics
and impact of
immunisation
programme
Description of the effects and
adverse events of the vaccine;
using the GRADE method.
Overall quality of the available
evidence of effects across all of the
outcomes, which are critical to
making a decision.
Are the desirable anticipated
effects large?
Are the undesirable anticipated
effects small?
What is the net beneﬁt of the
vaccination?
What is the overall certainty of this
evidence (e.g., how conﬁdent we
are about the net beneﬁt of the
vaccination)?
- Vaccine characteristics or properties (e.g.,
components, types, target population, posology).
- Efﬁcacy (e.g., immunogenicity, strain coverage,
capacity to reduce the disease incidence, capacity to
disrupt carriage, duration of protection, serotype
replacements).
-  Safety (e.g., reactogenicity, adverse events,
interaction with other vaccines)
Values and preferences Consideration of values and
preferences of patients/care givers
about the balance between
desirable and undesirable effects of
the vaccine.
How certain is the relative
importance of the desirable and
undesirable outcomes?
Would patients/caregivers feel that
the beneﬁts outweigh the harms
and burden?
What is the appreciation and value
of the vaccination in the
population?
- Values and preferences of citizens about the balance
between desirable and - undesirable effects of the
vaccine.
-  Perspectives and perceptions of the citizens and
health professionals about the disease and the vaccine.
Resource use All the information about costs, use
of resources and health outcomes
gained.
Is the incremental cost small
relative to the net beneﬁts?
Is  the total cost (impact on budget)
small?
What are the costs of the
vaccination and are they limited
compared to the beneﬁts?
- Vaccination costs (e.g., costs of the vaccine,
administration costs, costs arising from potential
adverse effects).
- Budget impact and ﬁnancial sustainability.
-  Health economic analyses (e.g., cost-effectiveness
analysis, cost-beneﬁt analysis, cost-utility analysis)
- Direct and indirect costs.
Equity Impact on health inequities and
ethical considerations.
What would be the impact on
health inequities?
Would some part of the population
taking advantage from the
vaccination compared to other
groups?
- Ethical considerations
- Equity (e.g., accessibility; equal distribution of
resources, beneﬁts risks, costs, etc. related to the
vaccination programme).
Feasibility Information on applicability and
possible barriers, acceptability,
organisational impact, alternative
scenarios, control system.
Is the option feasible to adoption in
the actual setting?
Which vaccination barriers or
facilitators act at the system level?
- Acceptability of the vaccination among the
population and health care professionals.
- Feasibility of the implementation of the programme
(e.g., vaccination coverage, ability to reach the
population target, vaccine availability and supply,
recommendation).
- Alternative interventions (e.g., effectiveness and
cost-effectiveness of alternatives).
- Surveillance system.
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wystematic reviews of frameworks is limited. Most studies were
eveloped only in the last 15 years. Most reviews incorporated
verlapping contents with a narrow focus. However, decision-
akers may  differ in the way they conceptualise their problems
nd approach decisions given the availability of support tools suit-
ble for use in other clinical areas as well. If vaccines are not
ifferent from other interventions, particularly drugs, a systematic
eview with a broader perspective might have added other rele-
ant elements. Our work serves as a starting point to deﬁne and
evelop a usable framework to inform vaccine coverage decisions.
uture directions involve addressing the above conceptual and
ethodological issues and increasing their broader applicability.
his process should include key stakeholders as well interna-
ional groups leading the development of support tools for clinical
ecision-making such as the GRADE and the DECIDE Working
roups [8,10].
Another consideration is that decisional frameworks quickly
volve, shaped by the changes in professional and social contexts as
ell as secular trends. For example, the EtD framework we used asa comparison tool was released as an interim version in December
2013 [8]; the ﬁnalised version has yet to be released and might
differ from the interim version.
5. Conclusions
The prospect for a framework to support coverage decisions
on vaccines is promising as national interests favour equitable
access to vaccines and drugs and reduce the threat posed by pre-
ventable diseases. Our study identiﬁed a number of frameworks
with a variety of dimensions. Burden of illness or problem, vac-
cine characteristics, values and preferences, resource use, equity
and feasibility are key factors. Our review highlights limitations
in the dimensions and criteria as well their lack of detailed and
pragmatic instructions for effective application in the evaluation
or comparison of vaccine strategies. Moving forward, future stud-
ies should evaluate ways to effectively communicate and support
the uptake of evidence pertaining to the selected dimensions and
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